Intravitreal bevacizumab treatment for refractory diabetic macular edema

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 4, 2008, Pages 403-407

  Örnek, Kemal ^a   Örnek, Nurgül ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b Maya Eye Center   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; PROSPECTIVE STUDY; VISUAL ACUITY;

AGED; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITREOUS BODY;

EID: 48349132374     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0128     Document Type: Article

References (24)

1. Tranos, P.G., Wickremasinghe, S.S., Stangos, N.T., et al. Macular edema. Surv. Ophthalmol. 49:470-490, 2004.
2. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. The Early Treatment Diabetic Retinopathy Study Research Group. Arch. Ophthalmol. 113:1144-1155, 1995.
3. Gillies, M.C., Sutter, F.K., Simpson, J.M., et al. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized, clinical trial. Ophthalmology 113:1533-8, 2006. Epub 2006 Jul 7.
4. Higuchi, A., Ogata, N., Jo, N., et al. Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide. Jpn. J. Ophthalmol. 50:529-531, 2006. Epub 2006 Dec 18.
5. Sorensen, T.L., Haamann, P., Villumsen, J., et al. Intravitreal triamcinolone for macular oedema: Efficacy in relation to aetiology. Acta. Ophthalmol. Scand. 83:67-70, 2005.
6. Schatz, H., Madeira, D., McDonald, H.R., et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch. Ophthalmol. 109:1549-1551, 1991.
7. Jeppesen, P., Bek, T. Impaired retinal autoregulation in small retinal arterioles before and after focal laser treatment for diabetic maculopathy. Br. J. Ophthalmol. 90:198-201, 2006.
8. Smithen, L.M., Ober, M.D., Maranan, L., et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am. J. Ophthalmol. 138:740-743, 2004.
9. Cekic, O., Chang, S., Tseng, J.J., et al. Cataract progression after intravitreal triamcinolone injection. Am. J. Ophthalmol. 139:993-998, 2005.
10. Joussen, A.M., Poulaki, V., Le, M.L., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18:1450-1452, 2004. Epub 2004 Jul 1.
11. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994.
12. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-2342, 2004.
13. Iturralde, D., Spaide, R.F., Meyerle, C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 26:279-284, 2006.
14. Spandau, U.H., Ihloff, A.K., and Jonas, J.B. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta. Ophthalmol. Scand. 84:555-556, 2006.
15. Silva Paula, J., Jorge, R., Alves Costa, R., et al. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta. Ophthalmol. Scand. 84:556-557, 2006.
16. Haritoglou, C., Kook, D., Neubauer, A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005, 2006.
17. Yoganathan, P., Deramo, V.A., Lai, J.C., et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26:994-998, 2006.
18. Mason, J.O., 3rd, Albert, M.A., Jr., and Vail, R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356-357, 2006.
19. Arevalo, J.F., Fromow-Guerra, J., Quiroz-Mercado, H., et al. Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750, 2007.
20. Byeon, S.H., Kwon, Y.A., Oh, H.S., et al. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J. Ocul. Pharmacol. Ther. 23:387-394, 2007.
21. Ahmadieh, H., Ramezani, A., Shoeibi, N., et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: A placebo-controlled, randomized, clinical trial. Graefe's Arch. Clin. Exp. Ophthalmol. 2007 Oct 5 [Epub ahead of print].
22. Soheilian, M., Ramezani, A., Bijanzadeh, B., et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27:1187-1195, 2007.
23. Paccola, L., Costa, R.A., Folgosa, M.S., et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br. J. Ophthalmol. 92:76-80, 2008. Epub 2007 Oct 26.
24. Audren, F., Erginay, A., Haouchine, B., et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta. Ophthalmol. Scand. 84:624-630, 2006.